België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

elanco - geïnactiveerd mycoplasma hyopneumoniae min. 6000 ur/dose - emulsie voor injectie - geïnactiveerd mycoplasma hyopneumoniae - mycoplasma - varken

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

octapharma gmbh elisabeth-selbert-str. 11 40764 langenfeld (duitsland) - plasma, humaan 45 - 70 mg/ml - oplossing voor infusie - glycine (e 640) ; natriumdiwaterstoffosfaat 2-water (e 339) ; trinatriumcitraat 2-water (e 331), - blood plasma

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

elanco gmbh - geÏnactiveerd mycoplasma hyopneumoniae, stam p-5722-3 - emulsie voor injectie - mycoplasma vaccine - varkens

Europese Unie - Nederlands - EMA (European Medicines Agency)

pharmsure veterinary products europe ltd - mycoplasma synoviae stam ms-h - immunologicals voor aves, levende bacteriële vaccins - kip - voor actieve immunisatie van toekomstige vleeskuikenkippen, toekomstige kweekkippen en toekomstige legkippen om luchtzaklaesies te verminderen en het aantal eieren met abnormale schilvorming veroorzaakt door mycoplasma synoviae te verminderen.

Europese Unie - Nederlands - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - varkens - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.